Effect of kidney failure and hemodialysis on protein and amino acid metabolism

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 15, Issue 1, 2012, Pages 78-84

  Garibotto, Giacomo ^a   Bonanni, Alice ^a   Verzola, Daniela ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Chronic kidney disease; Hemodialysis; Protein energy wasting; Skeletal muscle

Indexed keywords

BRANCHED CHAIN AMINO ACID; DIMETHYLARGININASE; HIGH DENSITY LIPOPROTEIN; INSULIN RECEPTOR SUBSTRATE; INTERLEUKIN 6; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MYOSTATIN; N(G),N(G) DIMETHYLARGININE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; S ADENOSYLHOMOCYSTEINE; SOMATOMEDIN C; VERY LOW DENSITY LIPOPROTEIN;

AMINO ACID METABOLISM; ANOREXIA; APOPTOSIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CELL REGENERATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DNA METHYLATION; ENDOCRINE DISEASE; ENDOTHELIAL DYSFUNCTION; ENZYME REGULATION; GENETIC REGULATION; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; KIDNEY FAILURE; LIPOPROTEIN METABOLISM; METABOLIC ACIDOSIS; MORTALITY; MUSCLE ATROPHY; MUSCLE CELL; MYOSITIS; PROTEIN CALORIE MALNUTRITION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN METHYLATION; PROTEINURIA; REVIEW; SKELETAL MUSCLE; SKELETAL MUSCLE SATELLITE CELL; UREMIA; VASCULAR DISEASE;

AMINO ACIDS; APOPTOSIS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; PROTEIN-ENERGY MALNUTRITION; PROTEINS; RENAL DIALYSIS; WASTING SYNDROME;

EID: 84857032765     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32834d9df6     Document Type: Review

References (41)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
2. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation 2011; 123: 2145-2156.
3. Garibotto G, Valli A, Anderstam B, et al. The kidney is the major site of S-adenosylhomocysteine disposal in humans. Kidney Int 2009; 76: 293-296.
4. Dwivedi RS, Herman JG, McCaffrey TA, Raj DS. Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int 2011; 79: 23-32.
5. Lu TM, Chung MY, Lin CC, et al. Asymmetric dimethylarginine and clinical outcomes in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1566-1572.
6. Luksha N, Luksha L, Carrero JJ, et al. Impaired resistance artery function in patients with end-stage renal disease. Clin Sci 2011; 120: 525-536.
7. Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nat Rev Drug Discov 2011; 10: 277-291.
8. Kaysen GA. New insights into lipid metabolism in chronic kidney disease. J Ren Nutr 2011; 21: 120-123.
9. Holzer M, Birner-Gruenberger R, Stojakovic T, et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011; 22: 1631-1641.
10. Ooi EM, Chan DT, Watts GF, et al. Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease. J Lipid Res 2011; 52: 794-800.
11. Mak RH, Cheung WW, Zhan JY, et al. Cachexia and protein-energy wasting in children with chronic kidney disease. Pediatr Nephrol 2011. doi: 10.1007/s00467-011-1765-5.
12. Suneja M, Murry DJ, Stokes JB, Lim VS. Hormonal regulation of energy-protein homeostasis in hemodialysis patients: an anorexigenic profile that may predispose to adverse cardiovascular outcomes. Am J Physiol Endocrinol Metab 2011; 300: 55-64.
13. Mitch WE. Metabolic and clinical consequences of metabolic acidosis. J Nephrol 2006; 19: 70-75.
14. Tessari P, Sofia A, Saffioti S, et al. Effects of chronic metabolic acidosis on splanchnic protein turnover and oxygen consumption in human beings. Gastroenterology 2010; 138: 1557-1565.
15. Reeds PJ, Cadenhead A, Fuller MF, et al. Protein turnover in growing pigs: effects of age and food intake. Br J Nutr 1980; 43: 445-455.
16. Lecker SH, Mitch WE. Proteolysis by the ubiquitin-proteasome system and kidney disease. J Am Soc Nephrol 2011; 22: 821-824.
17. Bailey JL, Zheng B, Hu Z, et al. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 2006; 17: 1388-1394.
18. Hu J, Du J, Zhang L, et al. XIAP reduces muscle proteolysis induced by CKD. J Am Soc Nephrol 2010; 21: 1174-1183.
19. Chen Y, Biada J, Sood S, Rabkin R. Uremia attenuates growth hormonestimulated insulinlike growth factor-1 expression, a process worsened by inflammation. Kidney Int 2010; 78: 89-95.
20. Chen Y, Sood S, Krishnamurthy VM, et al. Endotoxin-induced growth hormone resistance in skeletal muscle. Endocrinology 2009; 150: 3620-3626.
21. Zhang L, Wang XH, Wang H, et al. Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol 2010; 21: 419-427.
22. Pedersen BK. The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochem 2006; 42: 105-117.
23. Carrero JJ, Ortiz A, Qureshi AR, et al. Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 110-118.
24. Garibotto G, Sofia A, Procopio V, et al. Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: effects of end-stage renal disease and microinflammatory state. Kidney Int 2006; 70: 384-390.
25. Raj DS, Moseley P, Dominic EA, et al. Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis. Kidney Int 2008; 73: 1054-1061.
26. Zhang L, Rajan V, Lin E, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011; 25: 1653-1663.
27. Verzola D, Procopio V, Sofia A, et al. Apoptosis and myostatin mRNA are upregulated in the skeletal muscle of patients with chronic kidney disease. Kidney Int 2011; 79: 773-782.
28. Reaich D, Channon SM, Scrimgeour CM, et al. Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol 1993; 265: 230-235.
29. Chen Y, Sood S, McIntire K, et al. Leucine stimulated mTOR signaling is partly attenuated in skeletal muscle of chronically uremic rats especially when work overloaded. Am J Physiol Endocrinol Metab 2011. doi: 10.1152/ajpendo.00068. 2011.
30. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2010; 1: 9-21.
31. Bruusgaard JC,Gundersen K. In vivo time-lapse microscopy reveals no loss of murine myonuclei during weeks of muscle atrophy. J Clin Invest 2008; 118: 1450-1457.
32. Bruusgaard JC, Johansen IB, Egner IM, et al. Myonuclei acquired by overload exercise precede hypertrophy and are not lost on detraining. Proc Natl Acad Sci U S A 2010; 107: 15111-15116.
33. Dukkipati R, Kopple JD. Causes and prevention of protein-energy wasting in chronic kidney failure. Semin Nephrol 2009; 29: 39-49.
34. Lim VS, Ikizler TA, Raj DS, Flanigan MJ. Does hemodialysis increase protein breakdown? Dissociation between whole-body amino acid turnover and regional muscle kinetics. J Am Soc Nephrol 2005; 16: 862-868.
35. Raj DS, Oladipo A, Lim VS. Amino Acid and protein kinetics in renal failure: an integrated approach. Semin Nephrol 2006; 26: 158-166.
36. Korevaar JC, van Manen JG, Dekker FW, et al., NECOSAD study group. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 2004; 15: 2916-2922.
37. Meuwese CL, Halbesma N, Stenvinkel P, et al. Variations in C-reactive protein during a single haemodialysis session do not associate with mortality. Nephrol Dial Transplant 2010; 25: 3717-3723.
38. Boivin MA, Battah SI, Dominic EA, et al. Activation of caspase-3 in the skeletal muscle during haemodialysis. Eur J Clin Invest 2010; 40: 903-910.
39. Gutierrez A, Alvestrand A, Wahren J, Bergström J. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990; 38: 487-494.
40. Mares J, Thongboonkerd V, Tuma Z, et al. Specific adsorption of some complement activation proteins to polysulfone dialysis membranes during hemodialysis. Kidney Int 2009; 76: 404-413.
41. Mares J, Richtova P, Hricinova A. Proteomic profiling of blood-dialyzer interactome reveals involvement of lectin complement pathway in hemodialysis-induced inflammatory response. Proteomics Clin Appl 2010; 4: 829-838.